These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Enhancement of 131I-MIBG uptake in carcinoid tumours by administration of unlabelled MIBG. Hoefnagel CA; Taal BG; Sivro F; Boot H; Valdes Olmos RA Nucl Med Commun; 2000 Aug; 21(8):755-61. PubMed ID: 11039459 [TBL] [Abstract][Full Text] [Related]
3. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063 [TBL] [Abstract][Full Text] [Related]
4. [Role of 131I-metaiodobenzylguanidine scintigraphy in the diagnosis of intestinal carcinoids]. Bihl H; Sautter-Bihl ML; Wilhelm KR; Kimmig B Nuklearmedizin; 1987 Dec; 26(6):263-7. PubMed ID: 3438170 [TBL] [Abstract][Full Text] [Related]
5. Meta-[131I]iodobenzylguanidine in the scintigraphic evaluation of neural crest tumors. Zagar I; Han R; Mitrovic S Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):13-6. PubMed ID: 9002742 [TBL] [Abstract][Full Text] [Related]
6. Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors. Lastoria S; Maurea S; Vergara E; Acampa W; Varrella P; Klain M; Muto P; Bernardy JD; Salvatore M Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):145-9. PubMed ID: 9002775 [TBL] [Abstract][Full Text] [Related]
7. Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice. Taal BG; Hoefnagel C; Boot H; Valdés Olmos R; Rutgers M Ann Oncol; 2000 Nov; 11(11):1437-43. PubMed ID: 11142484 [TBL] [Abstract][Full Text] [Related]
8. Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma. Von Moll L; McEwan AJ; Shapiro B; Sisson JC; Gross MD; Lloyd R; Beals E; Beierwaltes WH; Thompson NW J Nucl Med; 1987 Jun; 28(6):979-88. PubMed ID: 3035114 [TBL] [Abstract][Full Text] [Related]
9. Efficient production of therapeutic doses of [131I]-metaiodobenzylguanidine for clinical use. Prabhakar G; Mathur A; Shunmugam G; Teje YD; Sachdev SS; Sivaprasad N Appl Radiat Isot; 2011 Jan; 69(1):63-7. PubMed ID: 20933432 [TBL] [Abstract][Full Text] [Related]
10. Successful and unsuccessful approaches to imaging carcinoids: comparison of a radiolabelled tryptophan hydroxylase inhibitor with a tracer of biogenic amine uptake and storage, and a somatostatin analogue. Macfarlane D; Gonin J; Wieland D; Mangner T; Froelich J; Beierwaltes W; Shapiro B Eur J Nucl Med; 1996 Feb; 23(2):131-40. PubMed ID: 8925846 [TBL] [Abstract][Full Text] [Related]
11. [Contribution of 131I MIBG scintigraphy in the diagnosis of carcinoid tumors of the digestive tract. Experience of 14 cases]. Siproudhis L; Lescouarc'h J; Bretagne JF; Bourguet P; Raoul JL; Etienne PL; Herry JY; Gosselin M Gastroenterol Clin Biol; 1991; 15(11):789-93. PubMed ID: 1769467 [TBL] [Abstract][Full Text] [Related]
12. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans. Monsieurs M; Brans B; Bacher K; Dierckx R; Thierens H Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1581-7. PubMed ID: 12458391 [TBL] [Abstract][Full Text] [Related]
13. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. Taal BG; Hoefnagel CA; Valdes Olmos RA; Boot H; Beijnen JH J Clin Oncol; 1996 Jun; 14(6):1829-38. PubMed ID: 8656251 [TBL] [Abstract][Full Text] [Related]